XML 38 R27.htm IDEA: XBRL DOCUMENT v3.5.0.2
Collaboration and Commercial Technology Licensing Agreements (Details)
1 Months Ended 3 Months Ended 9 Months Ended
Oct. 28, 2016
Jul. 31, 2016
USD ($)
Jun. 30, 2016
USD ($)
item
Sep. 30, 2016
USD ($)
Jun. 30, 2016
USD ($)
Jun. 30, 2015
USD ($)
Mar. 31, 2015
USD ($)
Dec. 31, 2013
USD ($)
Sep. 30, 2016
USD ($)
Sep. 30, 2015
USD ($)
Collaboration payments and costs                    
Purchase of other investments                 $ 6,100,000  
Subordinated convertible promissory notes                    
Collaboration payments and costs                    
Purchase of other investments   $ 6,100,000                
Specimen transfer agreements                    
Collaboration payments and costs                    
Collaboration expense         $ 1,400,000 $ 1,400,000     3,900,000 $ 10,800,000
Technology license agreements                    
Collaboration payments and costs                    
Costs recorded under collaborative arrangements         95,000 $ 2,300,000     5,200,000 6,900,000
Technology license agreements | Roche                    
Collaboration payments and costs                    
Period of time to give notice to terminate agreement 30 days                  
Exclusive license agreement                    
Collaboration payments and costs                    
Collaboration expense                   $ 5,500,000
Estimated total remaining obligation, including milestone payments                 $ 0  
Exclusive license agreement | Research and development expense.                    
Collaboration payments and costs                    
Up-front payment               $ 9,000,000    
Milestone payment             $ 5,500,000      
Oncotype DX DCIS clinical study                    
Collaboration payments and costs                    
Period from achieving key milestone entity required to make fixed annual payments                 1 year  
Final payment                 $ 504,000  
Exclusive distribution rights Epic's AR-V7 liquid biopsy test in United States                    
Collaboration payments and costs                    
Obligation upon achievement of certain milestones     $ 4,000,000   4,000,000          
Number of milestones needed to be achieved for conversion into preferred stock | item     1              
Investment in preferred stock per collaboration agreement     $ 2,500,000   2,500,000          
Term of agreement     10 years              
Exclusive distribution rights Epic's AR-V7 liquid biopsy test in United States | Subordinated convertible promissory notes                    
Collaboration payments and costs                    
Investment in subordinated convertible promissory notes per agreement     $ 7,500,000   $ 7,500,000          
Purchase of other investments       $ 6,100,000         6,100,000  
Estimated fair value       5,800,000         5,800,000  
Deferred cost       $ 305,000         $ 305,000